BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17351402)

  • 1. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
    Lin CC; Hsu CH; Huang CY; Keng HY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Anticancer Drugs; 2007 Apr; 18(4):487-91. PubMed ID: 17351402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
    Pagliaro LC; Millikan RE; Tu SM; Williams D; Daliani D; Papandreou CN; Logothetis CJ
    J Clin Oncol; 2002 Jul; 20(13):2965-70. PubMed ID: 12089226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Pectasides D; Aravantinos G; Kalofonos H; Kiamouris C; Bafaloukos D; Xiros N; Nicolaides C; Visvikis A; Dimopoulos MA
    Ann Oncol; 2001 Oct; 12(10):1417-22. PubMed ID: 11762814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
    Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
    J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
    Polyzos A; Tsavaris N; Gogas H; Lagadas A; Polyzos K; Giannakopoulos K; Felekouras E; Tsigris C; Karatzas T; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2009 Jul; 29(7):2681-6. PubMed ID: 19596946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
    Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
    Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
    Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
    Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
    Hahn NM; Stadler WM; Zon RT; Waterhouse D; Picus J; Nattam S; Johnson CS; Perkins SM; Waddell MJ; Sweeney CJ;
    J Clin Oncol; 2011 Apr; 29(12):1525-30. PubMed ID: 21422406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.